SHENGJIE SONG, ZHIZHOU SHI^*

BIOCELL, Vol.47, No.10, pp. 2207-2215, 2023, DOI:10.32604/biocell.2023.027677

Abstract Metabolic reprogramming frequently occurs in the majority of cancers, wherein fatty acid oxidation (FAO) is usually induced and serves as a compensatory mechanism to improve energy consumption. Carnitine palmitoyltransferase 1A (CPT1A) is the rate-limiting enzyme for FAO and is widely involved in tumor growth, metastasis, and chemo-/radio-resistance. This review summarizes the most recent advances in understanding the oncogenic roles and mechanisms of CPT1A in tumorigenesis, including in proliferation and tumor growth, invasion and metastasis, and the tumor microenvironment. Importantly, CPT1A has been shown to be a biomarker for diagnosis and prognosis prediction and proved to More > Graphic Abstract

YUANYUAN JIA, XIAONA MA, XIURUI YAN, JING XUE, TINGTING YANG, XUEYUN LIANG^*, XIAOMING LIU^*

BIOCELL, Vol.46, No.2, pp. 479-493, 2022, DOI:10.32604/biocell.2022.015390

Abstract Mesenchymal stem cells (MSCs) capable of tumour topotaxis have been served as cellular vehicles to deliver anti-tumour agents. As cellular components of the tumour microenvironment, MSCs also affect tumour progression. However, the tumour transformation-related genes of MSCs remain unclear since either tumorigenic or tumour suppressor effects within these cells have been researched. Hence, we aimed to identify potential biomarkers indicative of tumorigenic risk by RNA-seq analysis of human placenta tissue-derived MSCs (hPTMSCs) exposed to the carcinogenic agent, 3-methylcholanthrene (3-MC). Twenty-nine tumour transformation-related genes and three pluripotency-related genes were appraised as differentially expressed genes (DEGs) in More >

Dongdong Zheng^1,#, Chi Shen^1,2,#, Wenshi Liu¹, Wenjing Lv¹, Xiaofei Li^1,*

Congenital Heart Disease, Vol.16, No.4, pp. 373-381, 2021, DOI:10.32604/CHD.2021.015260

Abstract Objectives: Pulmonary arterial hypertension in congenital heart disease (PAH-CHD) is the most common type of PAH and increases morbidity and mortality in patients with CHD. Right heart catheterization (RHC) is the standard method to diagnose PAH. However, RHC is an invasive and complicated method with relatively high cost. Noninvasive, feasible, and cost-efficient methods are urgently needed. The objective of this study was to evaluate three potential biomarkers of PAH-CHD: Hepatocyte growth factor (HGF), osteopontin (OPN), and suppression of tumorigenicity 2 (ST2). Methods: Plasma samples were collected from patients with CHD (n = 46) and healthy individuals (n… More >

Shivangi Goyal, Sreemoyee Chatterjee, Nidhi Gupta^*

Oncologie, Vol.23, No.1, pp. 89-104, 2021, DOI:10.32604/Oncologie.2021.015234

Abstract Background: Trigonella foenum-graecum Linn. has been extensively used for medicinal purposes. The current study deals with in vitro and in vivo correlation of free radical quenching activity and anticancer potential of seed extracts of Trigonella. Materials and methods: Antioxidant activity was evaluated against DPPH, NO and ABTS via in vitro radical scavenging assay. Cytotoxicity effect of Trigonella seed extract was studied in human embryonic kidney HEK 293 cell line by alamar blue assay. In vivo antioxidant activity in Swiss albino mice model was assessed by studying endogenous antioxidant enzymes such as GSH, GPx, SOD and LPO. Antitumor effect was observed by studying parameters… More >

Dong Li^*1, Fei-fan Sun^*1, Dan Wang^*1, Tao Wang^*, Jing-jing Peng^*, Jian-Qiong Feng^*, Hua Li^*, Chao Wang^†, Dai-jun Zhou^*, Hong Luo^*, Zeng-qiang Fu^*, Tao Zhang^*

Oncology Research, Vol.28, No.5, pp. 467-481, 2020, DOI:10.3727/096504020X15925659763817

Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug… More >

Dong Li^*1, Fei-fan Sun^*1, Dan Wang^*1,Tao Wang^*, Jing-jing Peng^*, Jian-Qiong Feng^*, Hua Li^*, Chao Wang^†, Dai-jun Zhou^*, Hong Luo^*, Zeng-qiang Fu^*, Tao Zhang^*

Oncology Research, Vol.28, No.7-8, pp. 827-828, 2020, DOI:10.3727/096504021X16280937554409

Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug… More >

Vinitha Richard, Rajesh Raju, Aswathy Mary Paul, Reshmi Girijadevi, Thankayyan Retnabai Santhosh Kumar, Madhavan Radhakrishna Pillai

Oncology Research, Vol.26, No.1, pp. 17-26, 2018, DOI:10.3727/096504017X14881490607028

Abstract This study is an integrated analysis of the transcriptome profile microRNA (miRNA) and its experimentally validated mRNA targets differentially expressed in the tumorigenic stem-like fraction of oral squamous cell carcinoma (OSCC). We had previously reported the coexistence of multiple drug-resistant tumorigenic fractions, termed side population (SP1, SP2, and MP2), and a nontumorigenic fraction, termed main population (MP1), in oral cancer. These fractions displayed a self-renewal, regenerative potential and expressed known stemness-related cell surface markers despite functional differences. Flow cytometrically sorted pure fractions of SP1 and MP1 cells were subjected to differential expression analysis of both… More >

Qifang Long^*, Weipei Zhu^*, Jundong Zhou^†, Jinchang Wu^†, Weixian Lu^‡, Cui Zheng^‡, Dongmei Zhou^‡, Ling Yu^‡, Ru Yang^‡

Oncology Research, Vol.25, No.4, pp. 595-603, 2017, DOI:10.3727/096504016X14765492198706

Abstract Ovarian cancer is one of the most lethal malignant gynecologic tumors with a high relapse rate worldwide. Cancer stem cells (CSCs) have been identified in ovarian cancer and other malignant tumors as a small population of cells that are capable of self-renewal and multidifferentiation. CD133⁺ ovarian CSCs have been reported to be more tumorigenic and more resistant to chemotherapeutic treatment. Thus, CD133 has emerged as one of the most promising therapeutic markers for ovarian cancer treatment. In the current study, we constructed a recombinant adenovirus Cre/loxP regulation system to selectively introduce truncated Bid (tBid) expression specifically… More >